Evercore Downgrades Twist Bioscience(TWST.US) to Hold Rating, Raises Target Price to $102
Evercore has downgraded its rating on Twist Bioscience (TWST.US) from Outperform to Hold. Despite the downgrade, the firm increased its price target for TWST.US to $102, up from the previous $90. This adjustment reflects Evercore's updated outlook on the company.
TWST - Twist Bioscience Corp Options
The article provides a snapshot of Twist Bioscience Corp (TWST) stock, detailing its latest close, financial performance metrics, and various technical and fundamental indicators. It includes information on market capitalization, income, sales, P/E ratios, employee count, and insider/institutional ownership, alongside price performance over different periods.
Twist Bioscience Corp. Actuals & Estimates (SWB:0ME)
This article provides an overview of Twist Bioscience Corp. (SWB:0ME) stock, including analyst forecasts, historical price data, and financial performance. It highlights key financial figures such as earnings per share and revenue for recent quarters, and notes that the company does not pay dividends. Investors can find details on future earnings dates and employee count.
Twist Bioscience stock hits 52-week high at 104.31 USD By Investing.com
Twist Bioscience (TWST) stock reached a new 52-week high of $104.31, reflecting a 175.61% increase over the past year. This surge is driven by strong investor confidence and positive analyst ratings, with several firms raising price targets due to the company's Q2 revenue beat and its innovative silicon-based technology applicable to AI. Despite this, InvestingPro suggests the stock may be overvalued and in overbought territory.
Twist Bioscience stock hits 52-week high at 104.31 USD
Twist Bioscience (TWST) stock has reached a new 52-week high of $104.31, reflecting a 175.61% increase over the past year. This surge is attributed to positive market sentiment and strong analyst ratings, with several firms raising their price targets on the biotech company. Despite being considered overvalued by InvestingPro Tips and showing an overbought RSI, analysts highlight the company's growth potential in DNA synthesis infrastructure, particularly with AI applications.
Cathie Wood’s ARK sells Twist Bioscience, buys Circle Internet stock
Cathie Wood's ARK ETFs made significant portfolio adjustments, selling over $11 million worth of Twist Bioscience stock while increasing holdings in Circle Internet Group Inc. and SoFi Technologies Inc. ARK also boosted its position in Recursion Pharmaceuticals Inc. but reduced its stake in 10X Genomics Inc., reflecting dynamic investment management.
Cathie Wood’s ARK buys Coinbase, sells Twist Bioscience stock
Cathie Wood's ARK ETFs made several strategic trades on June 29, 2026, significantly increasing its holdings in Coinbase Global Inc and Circle Internet Group Inc, and CoreWeave Inc, signaling continued confidence in digital assets and cloud computing. Conversely, ARK reduced its positions in Twist Bioscience Corp, 10X Genomics Inc, and Alibaba Group Holding Ltd, indicating a reallocation of funds. These dynamic adjustments reflect ARK's balanced approach to optimizing its portfolio across high-growth tech sectors and other defense and energy interests like Kratos Defense and Security Solutions Inc and X-Energy Inc.
Is Twist Bioscience’s (TWST) New ATM Shelf Reshaping Its Capital Structure Or Just Adding Flexibility?
Twist Bioscience (TWST) recently filed a universal shelf registration and an at-the-market (ATM) equity offering for up to US$200 million. This move provides the company with significant financial flexibility, which is crucial given its continued losses despite revenue growth. The financing capacity aims to support investments in new offerings and growth, but also introduces the risk of dilution for existing shareholders.
Price to earnings forward of Twist Bioscience Corporation – NASDAQ:TWST
This article provides financial information for Twist Bioscience Corporation (NASDAQ: TWST) on TradingView. It specifically focuses on the company's price to earnings forward metric. The content includes general financial and market data, but not specific numeric values for the forward PE ratio.
Form 4 Twist Bioscience Corp For: 26 June By Investing.com
This article reports on a Form 4 filing for Twist Bioscience Corp, dated June 26, 2026. Form 4 filings disclose changes in ownership of company stock by insiders. The article includes the stock symbol TWST and its performance, but no further details about the filing itself.
Twist Bioscience Stock Rises as Investors Continue to Reward Stronger Growth Outlook and Margin Progress
Twist Bioscience (TWST) stock increased following an analyst's reiterated "buy" rating and price target increase, driven by improved growth and margin outlooks. The company is benefiting from increased demand in its Synthetic Biology segment and its next-generation sequencing products, with significant potential in its antibody discovery business. Despite historical unprofitability, analysts are optimistic about its future profitability and expanded growth opportunities.
Form 4 Twist Bioscience Corp For: 26 June By Investing.com
This article provides details of a Form 4 filing for Twist Bioscience Corp, indicating insider transaction activity on June 26th. The primary content consists of financial market data including stock performance for Twist Bioscience (TWST) and various global indices, commodities, and currency pairs. It also features trending articles and market movers.
Twist Bioscience CEO Emily Leproust sells $1.79m in stock
Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), sold $1.79 million worth of common stock on June 25, 2026, through a pre-established trading plan. This sale occurred while the stock was trading near its 52-week high, having surged 205% year-to-date. Despite the strong performance, an InvestingPro analysis suggests the stock is currently overvalued.
Price to sales forward of Twist Bioscience Corporation – NASDAQ:TWST
This article provides a brief financial overview of Twist Bioscience Corporation (NASDAQ: TWST), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a section from a larger financial data platform like TradingView, offering a snapshot of a key valuation metric for the company. The content itself is very minimal, presenting only the metric's title without any actual numerical data or analysis.
Form 4 Twist Bioscience Corp For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Twist Bioscience Corp (TWST) on June 26. The brief piece indicates that the stock was up 3.30% following the news. It is a very short announcement typical of financial news services regarding regulatory filings.
Price to book forward of Twist Bioscience Corporation – NASDAQ:TWST
This article provides access to the "Price to book forward" financial metric for Twist Bioscience Corporation (NASDAQ: TWST) on the TradingView platform. It details the company's stock market information and indicates that the market was closed at the time of publication, showing no trades. The content primarily serves as a gateway to financial data and tools available on TradingView.
Twist Bioscience CEO Emily Leproust sells $1.79m in stock By Investing.com
Emily M. Leproust, CEO and Director at Twist Bioscience Corp (NASDAQ:TWST), sold 18,880 shares of common stock for $1,793,600 on June 25, 2026, under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-week high, having surged 205% year-to-date. In other news, the company reported strong Q2 revenues and has received positive analyst updates, with several firms raising price targets due to Twist Bioscience's strategic positioning in AI-driven biotech and its proprietary technology.
Insider Sell: Dennis Cho Sells 14,205 Shares of Twist Bioscience Corp (TWST)
Dennis Cho, an insider at Twist Bioscience Corp (TWST), sold 14,205 shares on June 24, 2026, reducing his total holdings to 105,141 shares. This sale is part of a trend for Cho, who has sold 55,524 shares in the past year with no purchases. The stock, currently trading at $89.75, is considered significantly overvalued with a price-to-GF-Value ratio of 1.88, based on GuruFocus's intrinsic value estimate of $47.84.
Twist Bioscience (TWST) CEO sells 18,880 shares under 10b5-1 plan
Twist Bioscience Corp CEO Emily M. Leproust reported selling 18,880 shares of common stock at $95.00 per share on June 25, 2026, under a pre-established Rule 10b5-1 trading plan. Following this transaction, she directly holds 824,039 common shares. The filing also detailed outstanding employee stock options with various strike prices and expiration dates.
Twist Bioscience (TWST) officer sells 14,205 shares in planned trade
Dennis Cho, an officer at Twist Bioscience (TWST), sold 14,205 shares of common stock on June 24, 2026, at a price of $89.75 per share, totaling approximately $1.27 million. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on February 17, 2026, indicating it was a pre-planned portfolio management action. Following the sale, Cho retains 105,141 shares directly.
Enterprise value to EBIT forward of Twist Bioscience Corporation – NASDAQ:TWST
This article provides financial data for Twist Bioscience Corporation (NASDAQ: TWST) on TradingView. It specifically highlights the company's enterprise value to EBIT forward. The content is presented within the TradingView platform's financial overview for the biotechnology stock.
Form 144 Twist Bioscience Corp For: 24 June By Investing.com
Investing.com reports on a Form 144 filing for Twist Bioscience Corp (TWST) dated June 24. A Form 144 indicates an intent to sell restricted securities, providing transparency regarding insider transactions. The article itself simply states the filing and provides common financial market data and advertisements.
Form 144 Twist Bioscience Corp For: 25 June By Investing.com
Investing.com has published a Form 144 filing for Twist Bioscience Corp (TWST) for June 25, 2026. The article itself is brief, primarily serving as a notification of the filing, and highlights the stock's current performance with a +5.80% change.
Emily Leproust (TWST) sells blocks of common stock totaling large proceeds in May‑June
Emily M. Leproust, an insider at Twist Bioscience Corp (TWST), reported multiple sales of common stock between April 21, 2026, and June 22, 2026, according to a recent Form 144 SEC filing. These transactions include significant sales such as 24,282 shares for over $1.5 million on May 26, 2026, and 25,017 shares for over $1.6 million on May 27, 2026. The filing indicates these are routine dispositions of affiliate shares, many originating from restricted stock vesting and ESPP purchases.
Form 4 Twist Bioscience Corp For: 24 June By Investing.com
This article announces the filing of Form 4 for Twist Bioscience Corp on June 24, as reported by Investing.com. It is a brief, factual notification typical of regulatory filing updates. The article itself provides no further details beyond the filing announcement.
Twist Bioscience SVP Paula Green sells $25,410 in common stock By Investing.com
Paula Green, SVP of HR at Twist Bioscience Corp, sold 291 shares totaling $25,410 to cover tax withholding obligations associated with Restricted Stock Units. This "sell to cover" transaction is mandated by company policy and not a discretionary trade. The sale occurred as TWST stock trades near its 52-week high after a 168% year-to-date surge, with several analysts maintaining positive ratings and raising price targets due to strong revenue growth and an optimistic long-term outlook.
Tax-related share sale by Twist Bioscience (TWST) chief executive
Twist Bioscience CEO Emily M. Leproust reported selling 1,688 shares of common stock at $87.3224 per share. This sale was non-discretionary and required to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans. After the transaction, Leproust still holds 842,919 shares directly and employee stock options for 64,950 additional shares.
Twist Bioscience (NASDAQ: TWST) SVP sells 291 shares to cover RSU taxes
Twist Bioscience's SVP of Human Resources, Paula Green, sold 291 shares of common stock at $87.3224 per share on June 22, 2026. This transaction was solely to cover tax withholding obligations associated with the vesting of Restricted Stock Units and was a mandated "sell to cover" action, not a discretionary trade. Following the sale, Green directly holds 120,414 shares of Twist Bioscience stock.
Dennis Cho of Twist Bioscience (NASDAQ: TWST) sells 346 shares to cover RSU taxes
Dennis Cho, an executive at Twist Bioscience (NASDAQ: TWST), sold 346 shares of common stock at an average price of $87.3224 per share. This transaction was a "sell to cover" sale, mandated to fulfill tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs), and not a discretionary trade. After the sale, Cho directly owns 119,346 shares of Twist Bioscience.
Director sells 14,205 shares; TWST reporting person lists multiple disposals (TWST)
A director of Twist Bioscience (TWST) reported multiple sales of Common Stock through Form 144 filings. The largest sale was 14,205 shares for $990,798.75 on May 29, 2026, with additional smaller sales occurring on various dates in May and June 2026. The filing also details numerous restricted stock vesting events from 2024, providing a comprehensive overview of insider dispositions and compensation.
Twist Bioscience Corp stock hits 52-week high at 89.71 USD
Twist Bioscience Corp (TWST) stock has reached a new 52-week high of $89.71, reflecting a 139.28% increase over the past year and a 168% year-to-date return, with a market capitalization of $5.5 billion. This surge is attributed to strong investor confidence and positive analyst coverage, with firms like TD Cowen, Canaccord Genuity, Piper Sandler, and Leerink raising price targets based on the company's Q2 revenue beat and innovative technology. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
Form 144 Twist Bioscience Corp For: 22 June By Investing.com
This article from Investing.com announces the filing of Form 144 for Twist Bioscience Corp on June 22. Form 144 is filed with the SEC when affiliates of a company plan to sell restricted or control securities. The article provides minimal detail beyond this announcement, typical for such regulatory notices.
Multiple insider sales and a 346-share vesting at TWST (NASDAQ: TWST)
A recent SEC Form 144 filing indicates a 346-share restricted stock vesting for Twist Bioscience Corp (NASDAQ: TWST) on June 18, 2026. The filing also disclosed multiple insider sales by Dennis H. Cho between May 4, 2026, and June 8, 2026, totaling over 18,000 shares with significant proceeds. These transactions are considered routine notices of planned dispositions.
Form 144 Twist Bioscience Corp For: 22 June By Investing.com
This article announces the filing of Form 144 for Twist Bioscience Corp (TWST) on June 22. Form 144 is a notice of the intent to sell restricted stock by insiders or affiliates. The content itself is very brief and mostly consists of various market data, ads, and navigation elements.
Insider sale notice for TWST (NASDAQ: TWST) shows recent dispositions
A Form 144 SEC filing for Twist Bioscience Corp (NASDAQ: TWST) indicates a proposed sale of 291 shares tied to restricted stock vesting on June 18, 2026. The filing also reports multiple dispositions by Paula Green over the past three months, including a significant sale of 26,137 shares on June 15, 2026, with listed proceeds of $2,134,485.95. These disclosures are procedural notices of intended resale activity and recent sales by an insider.
Emily Leproust sells TWST shares (NASDAQ: TWST) in multiple trades
Emily Leproust, an insider at Twist Bioscience Corp (NASDAQ: TWST), reported multiple sales of common stock through Form 144 filings. These transactions, occurring between April and June 2026, include significant dispositions such as 24,282 shares for $1,580,245.85 and 25,017 shares for $1,633,407.46. Additionally, a restricted stock vesting of 1,688 shares was reported on June 18, 2026.
Form 144 Twist Bioscience Corp For: 22 June By Investing.com
This article consists solely of the title "Form 144 Twist Bioscience Corp For: 22 June" repeated multiple times, alongside various financial market data and news headlines. It indicates that Twist Bioscience Corp's stock (TWST) was down 2.73% and shows a timestamp for its publication. The core content is a very short announcement regarding a Form 144 filing for Twist Bioscience Corp on June 22nd.
Investor’s Favored Twist Bioscience’s (TWST) Association with Technology Companies
Osterweis Capital Management, in its Q1 2026 investor letter for its Osterweis Opportunity Fund, highlighted Twist Bioscience Corporation (NASDAQ: TWST) as a significant contributor to its performance. The biotech company, which specializes in synthetic DNA, saw strong gains due to its position in liquid biopsy and its role as an outsourced wet lab for technology companies building genomic databases for AI models. Despite its strong performance, the fund suggests that some AI stocks may offer greater upside potential with less downside risk.
Investor’s Favored Twist Bioscience’s (TWST) Association with Technology Companies
Osterweis Capital Management highlighted Twist Bioscience Corporation (NASDAQ: TWST) as a significant contributor in its Q1 2026 investor letter. The company specializes in synthetic DNA-based products and is gaining traction by outsourcing its "wet lab" services to technology companies building genomic databases for AI models. Twist Bioscience reported strong Q1 performance, with shares up 44.56% in one month and 152.77% over the past year, reflecting its growth in an expanding market.
TWST - Twist Bioscience Corp Stock Price and Quote
This Finviz.com page provides a detailed overview of Twist Bioscience Corp (TWST) stock, including its latest price, key financial metrics, performance over various periods, and analyst ratings. It also features a comprehensive list of recent corporate news and insider trading activities.
Twist Bioscience Corp Files For Mixed Shelf
Twist Bioscience Corp has filed for a mixed shelf. This Reuters news brief, less than a minute long, indicates a financial filing activity for the company, identified by the stock symbol TWST. The full details are available to users who sign in or create a free account.
Twist Bioscience (TWST) sets $200M ATM program with TD Cowen
Twist Bioscience (TWST) has established a $200 million at-the-market (ATM) equity program with TD Cowen, allowing it to sell common stock periodically. The company plans to use the proceeds for general corporate purposes, including working capital and potential acquisitions. An illustrative example suggests selling about 2.35 million shares at $84.95 each, which would result in an immediate dilution of $76.37 per share for new investors.
Twist Bioscience: Huge Downside, With Little Hope Of Profits (NASDAQ:TWST)
Twist Bioscience (TWST) is considered vastly overvalued, trading at 11x revenue despite consistent operating losses and no clear path to profitability. The company's adjusted EBITDA break-even target for September appears challenging, with recent quarters showing negative $13M adjusted EBITDA and minimal projected revenue growth. Even under a bull case with 8% operating margins, the fair value is estimated at $38 per share, suggesting significant downside from current levels, largely due to speculative AI enthusiasm rather than strong fundamentals.
Twist Bioscience (TWST) HR chief sells shares after exercising options
Twist Bioscience's SVP of Human Resources, Paula Green, exercised employee stock options for 26,137 shares and subsequently sold all of them in open-market transactions on June 15, 2026. The sales were conducted at weighted average prices of $81.6233 and $82.1655 per share, following an exercise price of $23.33 per share. After these transactions, Green directly owns 120,705 shares of Twist Bioscience common stock.
Twist Bioscience Corp (TWST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Twist Bioscience Corp (TWST), categorizing its revenue by business segments and geographical regions. As of FY2026Q1, NGS applications contributed 50.76% of revenue, while DNA synthesis and protein solutions accounted for 49.24%. Regionally, the Americas generated 56.30% of revenue, EMEA 37.00%, and APAC 6.70%.
Twist Bioscience stock hits 52-week high at 80.79 USD
Twist Bioscience's stock recently hit a 52-week high of $80.50, reflecting a 127% increase over the past year and strong investor confidence, though InvestingPro analysis suggests it may be overvalued. The company reported a 19% revenue increase in Q2, surpassing estimates, and has received multiple raised price targets from analysts due to its strategic advancements and growth projections. Management anticipates revenue to reach approximately $1 billion by fiscal year 2031.
Twist Bioscience (TWST) Stock Could Be 25.5% Overvalued After Its Recent Rally
Twist Bioscience (TWST) stock recently rallied significantly, with a 64.31% return over 30 days, placing its shares around $80.79. While some valuation models suggest it might be overvalued by 25.5% based on a fair value of $64.38, others, like the SWS DCF model, indicate it could be undervalued with a fair value of $138.31. Investors are encouraged to review underlying data and consider the execution risks, including ongoing net losses and customer concentration, before making investment decisions.
Twist Bioscience (TWST) Stock Could Be 25.5% Overvalued After Its Recent Rally
Twist Bioscience (TWST) stock has seen a significant rally, with shares reaching $80.79 after sharp momentum in recent months. While a popular narrative suggests the stock is 25.5% overvalued with a fair value of $64.38, a different discounted cash flow model suggests it is undervalued with a fair value of $138.31. Investors are encouraged to review the underlying data and risks, including ongoing net losses, to determine their stance on the stock.
TWST (NASDAQ) insider to sell 26,137 shares via option exercise on 06/15/2026
A recent SEC Form 144 filing indicates that an insider at Twist Bioscience Corp (TWST) plans to sell 26,137 shares of common stock through a stock option exercise on June 15, 2026. The transaction will be handled by Fidelity Brokerage Services LLC. The filing also details prior dispositions by Paula Green, totaling 3,696 shares sold between March and June 2026.
TWST Maintained by TD Cowen -- Price Target Raised to $89.00
TD Cowen has maintained a 'Buy' rating for Twist Bioscience (TWST) and raised its price target significantly from $68.00 to $89.00, reflecting optimism about the company's future. Despite this positive analyst sentiment, GuruFocus indicates that TWST is 70.8% overvalued with a current price of $81.36 against a GF Value™ of $47.63. Insider activity also shows significant selling, raising concerns for potential investors, suggesting caution despite strong growth and momentum scores.
